(RTTNews) - Medtronic plc (MDT) announced the U.S. Food and Drug Administration approval for Simplera continuous glucose monitor, or CGM, the company's first disposable, all-in-one CGM that's half the ...

Over the past five years, diabetes-focused medical device specialist DexCom (NASDAQ: DXCM) has made meaningful progress on several fronts. The company launched new products in the continuous glucose ...

Please provide your email address to receive an email when new articles are posted on . The FDA granted marketing approval to allow the Eversense E3 CGM to be integrated with insulin delivery systems.

The first fully implantable continuous glucose monitors can now be integrated with insulin pumps as part of an automated insulin delivery system As the first fully implantable device in the category, ...

GALWAY, Ireland, April 24, 2025 /PRNewswire/ -- Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced it has submitted 510(k) applications to the U.S. Food and Drug ...

DexCom's devices are incredibly valuable to diabetes patients. The company should continue to increase its addressable market. The stock's valuation looks as reasonable as it has in almost three years ...

A continuous glucose monitor is a better option than pricking your finger daily. These wearable devices are stuck to your arm and connect to an app on your smartphone or Apple Watch to easily test ...

DexCom has barely scratched the surface of its niche in the diabetes market. As a result of industry challenges, the stock's valuation has now come down. But from here, the stock looks well-positioned ...

With a single sensor, the Eversense 365 system provides one year of use, versus 10-14 days with short-term CGM’s for minimal life disruption “The approval of Eversense 365 represents a significant ...

DexCom will likely make significant headway in its addressable market in the next five years. The company should also increase its reach by launching new products and entering new countries. Despite a ...